Akesobio (09926.HK): Phase III Trial of Ivonescimab Combined with Chemotherapy Achieves Statistically Significant Positive OS Results

NewTimeSpace News: On August 26, 2026,Akesobio(09926.HK) announced that the global‑first‑in‑class bispecific antibody Ivonescimab combined with chemotherapy versus dostarlimab plus chemotherapy for first‑line advanced biliary tract cancer in the Phase III study (AK112‑309/HARMONi‑GI1) has been assessed by the Independent Data Monitoring Committee. The trial achieved the primary endpoint of overall survival with statistically significant and clinically meaningful positive outcomes. It also met all key secondary endpoints including progression‑free survival and objective response rate.

According to the announcement, this marks Ivonescimab’s first positive Phase III result in gastrointestinal tumours, following four positive Phase III outcomes previously obtained in lung‑cancer indications.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.